Zoetis — Business Overview

What does Zoetis do?

Zoetis is the world's largest animal health company by revenue, selling medicines, vaccines, and diagnostics for both pets and farm animals. Spun out of Pfizer in 2013 after nearly 75 years as a business unit within that company, Zoetis now operates independently and serves customers across more than 100 countries. Its roughly 300 product lines cover eight species — dogs, cats, horses, cattle, swine, poultry, fish, and sheep — and seven major product categories including parasiticides (flea/tick prevention), vaccines, dermatology treatments, anti-infectives (antibiotics and antifungals), pain management, and diagnostics.

The company operates through two reporting segments, split by geography, with a strong tilt toward companion animals (pets).

Across the whole company, companion animal products account for roughly 70% of revenue and livestock products for 29%.

How does Zoetis make money?

Zoetis sells branded prescription and over-the-counter animal health products directly to veterinarians, livestock producers, and distributors, who then resell to end users like pet owners and farmers. The business is largely self-pay — meaning purchases are not reimbursed by insurance as in human medicine — which keeps pricing power with the brand. The company's largest single customer, a U.S. veterinary distributor, represented about 16% of total 2025 revenue.

A handful of blockbuster products carry an outsized share of revenue. The top two product lines — Simparica/Simparica Trio (a flea, tick, and parasite chewable for dogs) and Apoquel/Apoquel Chewable (an itch-relief drug for dogs) — contributed roughly 16% and 12% of total revenue respectively in 2025. The top five product lines together accounted for about 42% of revenue, and the top ten for 57%. This concentration means a few key franchises drive a lot of the business, but the portfolio is diversified enough that no single product is existential on its own.

Zoetis also generates a small but growing stream of revenue from diagnostics and technology. Its Vetscan line of point-of-care diagnostic instruments and its AI-powered Vetscan Imagyst platform — which can analyze skin samples, fecal matter, urine, and blood — are sold into veterinary clinics. The company spent $698 million on R&D in 2025, prioritizing both entirely new compounds and lifecycle extensions of existing products (new species, new formulations, new claims).

What market does Zoetis operate in?

Zoetis operates in the global animal health market, which covers medicines, vaccines, and diagnostics for both companion animals and livestock. The filing does not quote an overall market size figure, but the company describes itself as the largest participant in this market by revenue. Growth in the companion animal segment is driven by rising pet ownership, increased spending on pet care, longer pet lifespans, and a deepening emotional bond between owners and pets — trends particularly prominent in developed economies. On the livestock side, demand is tied to global population growth, rising protein consumption in emerging markets, and the need for food security and sustainable production.

Several secular tailwinds support the industry. Approximately 60% of infectious diseases in humans originate in animals (per the CDC), which makes animal health a public health priority — amplifying investment in vaccines and treatments that cross species lines. The filing highlights avian influenza (H5N1 and H5N2) as an active area where Zoetis has already supplied vaccines to U.S. government agencies. Meanwhile, rising standards of living in emerging markets are expanding the middle class of pet owners globally and increasing demand for quality animal protein, both of which expand Zoetis's addressable market over time.

Who are Zoetis's main competitors?

The animal health industry is moderately consolidated at the top, with four major players and a long tail of smaller competitors. Zoetis's primary named competitors are:

• Boehringer Ingelheim Animal Health (private, part of a large German pharma group)
• Merck Animal Health (division of Merck & Co.)
• Elanco Animal Health (standalone public company)
• IDEXX Laboratories (primarily diagnostics)

Beyond these, dozens of mid-sized regional companies and a growing number of startups with narrower focuses compete in specific product categories or geographies.

Generic competition exists but is structurally less threatening than in human pharma. There is no large, well-funded generics company focused specifically on animal health. The filing explains why: individual animal health products tend to have smaller market sizes than human drugs, distribution requires direct veterinarian relationships and education, and the business is primarily self-pay. That said, Zoetis does face generic erosion on older products — its livestock antibiotic Draxxin and the injectable version of its anti-nausea drug Cerenia have both seen generic entrants after patent expiration. The company counters this with strong brand loyalty among vets and pet owners, and by continuously innovating on existing franchises.

Zoetis's stated competitive advantages include scale, R&D breadth, and a portfolio of first-in-class biologics. It holds more than 5,500 granted patents across 50+ countries and maintains a portfolio of novel monoclonal antibody (mAb) therapies — Librela, Solensia, Cytopoint — for which there are no direct animal health equivalents on the market.

Where does Zoetis operate?

Zoetis is a genuinely global business, with operations in more than 100 countries and direct commercial presence in approximately 45. The U.S. is the single largest market at 54% of revenue, but international operations (45% of revenue) span Europe, Asia-Pacific, Latin America, and beyond. Key international markets by revenue include Brazil ($393M), Australia ($329M), the U.K. ($325M), Germany ($236M), China ($227M), and Canada ($290M).

The company both manufactures and sells in many geographies, with 21 company-owned or leased manufacturing sites worldwide. Sites are located in the U.S. (California, Iowa, Michigan, North Carolina, Nebraska, Illinois), Ireland (three sites), Norway (two sites), Australia (two sites), Brazil, Italy, Belgium, Spain, China, and New Zealand. Over 90 third-party contract manufacturers (CMOs) supplement this internal network. R&D operations are co-located at several of these manufacturing sites to ease the transfer from lab to commercial production.

Currency fluctuation and geopolitical exposure are flagged as real risks for the international business. The filing notes that operations outside the U.S. face currency risk, capital controls, and varying regulatory regimes. The company also discloses that it conducts some business in Iran and Russia under specific U.S. government licenses — a narrow but notable geopolitical exposure. Regulatory requirements in China are described as "increasingly stringent," which could affect the pace of product approvals and growth there.